auf der Homepage von Michael Wöbke
TNF alpha receptor Etanercept: General overview The group of the TNF alpha tailors to which also Etanercept belongs show a considerable progress for the treatment of rheumatischer illnesses. This modern therapeutic intervenes straight in the inflammation processes. Acute discomfort decreases and in the long term drugs like Etanercept can stop even the other progress of cartilage destruction and osseous destruction. In the meantime, on grounds of his good effectiveness Etanercept is admitted for different areas of application. An essential part of the symptoms with the rheumatoiden arthritis, the Morbus Bechterew, the Psoriasis arthritis and the plaque Psoriasis is caused by inflammation-supporting molecules. They are a component one by the messenger's material tumour necrosis factor alpha (TNF alpha) of controlled network. As a token of an inflammatory immune answer the TNF alpha concentration is clearly raised with these illnesses in the gel chin skin (Synovialis) and in the blood serum. The similar is also valid for the skin phenomena of the Psoriasis arthritis: Here the tumour necrosis factor is in psoriatisch to changed skin districts of (Psoriasis-Plaques) in comparison to the healthy skin increases provably. Which function fulfils TNF alpha? TNF alpha is produced in the body mainly by Makrophagen (Fresszellen). Makrophagen are cells of the immune system which play an important role with defensive processes. Nearly all cells of our body own receptors for TNF alpha in her surface. To unfold his biological effect in the cells, TNF alpha must bind to these receptors. So variously as the appealed cells are also the effects provided by this messenger's material: TNF alpha is involved, for example, in the defence of tumour illnesses and infections, with the sore healing and with the strengthening of inflammation reactions. It can look activating as well as restraining. The human body creates it under normal terms that always only the desired messenger's material effects enter. For it there exists a complicated network of different regularisation mechanisms and controlling mechanisms. Beside inflammation-supporting Zytokinen there are as anti-inflammatory messenger's materials.Besides, the fine regularisation of the inflammation events can be supported by so-called dissolvable receptors. What do make dissolvable receptors? If the TNF alpha concentration increases, it comes, for example, for the separation of the cell-engaged TNF alpha receptors of the cell surface. These receptors umherschwimmenden freely now bind the tumour necrosis factor, even before he reaches the cell-constant receptors. The passing on of the TNF messages to the cell is prevented so and the biological effectiveness is neutralised. This fine balance seems to have lost with illnesses like the rheumatoiden arthritis the balance. Though the concentrations of the TNF opponents are also raised in the affected joints, nevertheless, they does not succeed any more in stopping the inflammatory processes permanently in the desired magnitude. These known processes serve the science as a basis to develop new therapy possibilities and to investigate them. On this way the dissolvable TNF alpha receptor Etanercept has originated. He is very similar to the of course seeming receptor. At the same time, however, Etanercept neutralises the messenger's material TNF alpha better without taking away from the body permanently too much of it. Egg white structure of Etanercept Etanercept is a biotechnological made substance whose structure is identical with human proteins (proteins). This minimises the immunonogene potential and with it the risk of reactions of the defensive system what means: Thus the appearance of allergic reactions can be avoided, on the one hand, during the therapy possibly and the security be raised. On the other hand this diminishes the danger of the defence reactions which could affect the effectiveness of the treatment.
Please, note that for the information to drugs and dosages no guarantee is taken over. This text raises no claim to completeness. The information shows no recommendation or application of the called preparation or the preparations and substances. The information do not substitute for the technical consultation with a doctor or chemist. For concrete and individual questions to the therapy you turn please to your doctor. Spring: "Etanercept - therapeutic uses in clinic and practise", jumper, ed.: Burmester. Sonderpubl. "Sure and actual long time therapy with rheumatoider arthritis", addition for Rheumatologen, jumper. Wyeth product information: Enbrel (state in 2005) author: Jumper medicine state: 20/01/2009